T. Rowe Price Associates’s Omnicell OMCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.07M Buy
62,095
+8,524
+16% +$357K ﹤0.01% 1807
2025
Q4
$2.43M Buy
53,571
+2,004
+4% +$73.3K ﹤0.01% 1667
2025
Q3
$1.57M Buy
51,567
+1,901
+4% +$58.4K ﹤0.01% 1840
2025
Q2
$1.46M Buy
49,666
+3,890
+8% +$116K ﹤0.01% 1798
2025
Q1
$1.6M Buy
45,776
+1,570
+4% +$62.2K ﹤0.01% 1720
2024
Q4
$1.97M Buy
44,206
+3,323
+8% +$149K ﹤0.01% 1658
2024
Q3
$1.78M Buy
40,883
+433
+1% +$16.3K ﹤0.01% 1698
2024
Q2
$1.09M Buy
40,450
+1,603
+4% +$46.4K ﹤0.01% 1860
2024
Q1
$1.14M Sell
38,847
-268,375
-87% -$8.14M ﹤0.01% 1860
2023
Q4
$11.6M Sell
307,222
-3,676
-1% -$135K ﹤0.01% 1066
2023
Q3
$14M Sell
310,898
-92,628
-23% -$5.61M ﹤0.01% 1001
2023
Q2
$29.7M Sell
403,526
-2,765
-0.7% -$186K ﹤0.01% 838
2023
Q1
$23.8M Sell
406,291
-89,244
-18% -$4.92M ﹤0.01% 873
2022
Q4
$25M Buy
495,535
+2,928
+0.6% +$176K ﹤0.01% 853
2022
Q3
$42.9M Buy
492,607
+2,855
+0.6% +$300K 0.01% 691
2022
Q2
$55.7M Sell
489,752
-33,741
-6% -$3.87M 0.01% 840
2022
Q1
$67.8M Sell
523,493
-36,020
-6% -$5.19M 0.01% 858
2021
Q4
$101M Sell
559,513
-46,000
-8% -$7.98M 0.01% 765
2021
Q3
$89.9M Sell
605,513
-37,024
-6% -$5.67M 0.01% 804
2021
Q2
$97.3M Sell
642,537
-64,087
-9% -$8.92M 0.01% 789
2021
Q1
$91.8M Sell
706,624
-17,166
-2% -$2.2M 0.01% 804
2020
Q4
$86.9M Sell
723,790
-10,331
-1% -$1.01M 0.01% 776
2020
Q3
$54.8M Buy
734,121
+9,622
+1% +$667K 0.01% 834
2020
Q2
$51.2M Buy
724,499
+443
+0.1% +$30.3K 0.01% 845
2020
Q1
$47.5M Sell
724,056
-6,021
-0.8% -$480K 0.01% 804
2019
Q4
$59.7M Buy
730,077
+18,634
+3% +$1.43M 0.01% 852
2019
Q3
$51.4M Buy
711,443
+28,845
+4% +$2.12M 0.01% 865
2019
Q2
$58.7M Buy
682,598
+10,042
+1% +$816K 0.01% 824
2019
Q1
$54.4M Buy
672,556
+10,617
+2% +$795K 0.01% 841
2018
Q4
$40.5M Sell
661,939
-3,075
-0.5% -$208K 0.01% 896
2018
Q3
$47.8M Sell
665,014
-11,240
-2% -$708K 0.01% 930
2018
Q2
$35.5M Buy
676,254
+3,096
+0.5% +$146K 0.01% 1013
2018
Q1
$29.2M Buy
673,158
+17,442
+3% +$802K ﹤0.01% 1054
2017
Q4
$31.8M Sell
655,716
-10,299
-2% -$520K 0.01% 1037
2017
Q3
$34M Buy
666,015
+92,582
+16% +$4.43M 0.01% 1003
2017
Q2
$24.7M Buy
573,433
+45,343
+9% +$1.88M ﹤0.01% 1091
2017
Q1
$21.5M Buy
528,090
+43,000
+9% +$1.58M ﹤0.01% 1129
2016
Q4
$16.4M Buy
485,090
+12,580
+3% +$433K ﹤0.01% 1201
2016
Q3
$18.1M Buy
472,510
+53,430
+13% +$1.99M ﹤0.01% 1171
2016
Q2
$14.3M Buy
419,080
+58,800
+16% +$1.83M ﹤0.01% 1203
2016
Q1
$10M Buy
360,280
+29,570
+9% +$812K ﹤0.01% 1268
2015
Q4
$10.3M Buy
330,710
+28,090
+9% +$829K ﹤0.01% 1277
2015
Q3
$9.41M Buy
302,620
+74,700
+33% +$2.67M ﹤0.01% 1319
2015
Q2
$8.6M Buy
227,920
+212,700
+1,398% +$7.76M ﹤0.01% 1384
2015
Q1
$534K Sell
15,220
-3,500
-19% -$115K ﹤0.01% 1954
2014
Q4
$620K Hold
18,720
﹤0.01% 1867
2014
Q3
$512K Hold
18,720
﹤0.01% 1927
2014
Q2
$537K Hold
18,720
﹤0.01% 1922
2014
Q1
$536K Hold
18,720
﹤0.01% 1895
2013
Q4
$478K Buy
18,720
+3,800
+25% +$90.8K ﹤0.01% 1925
2013
Q3
$353K Sell
14,920
-6,000
-29% -$134K ﹤0.01% 2034
2013
Q2
$430K Buy
+20,920
New +$386K ﹤0.01% 1916

Other funds holding OMCL

T. Rowe Price Associates's OMCL Position: Q1 2026 in Review

T. Rowe Price Associates increased its Omnicell (OMCL) stake by 16% in Q1 2026, buying an estimated $357K and bringing the position to 62,095 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1807.

T. Rowe Price Associates first reported a position in OMCL in Q2 2013 and has held it in 52 quarters since. The position peaked at $101M in Q4 2021. 272 funds tracked by Wall St. Rank hold OMCL as of Q1 2026.

  • T. Rowe Price Associates held 62,095 shares of Omnicell worth $2.07M as of Q1 2026.
  • T. Rowe Price Associates bought 8,524 Omnicell shares in Q1 2026, an estimated $357K.
  • Omnicell made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1807 holding.
  • T. Rowe Price Associates first reported a position in Omnicell in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Omnicell position peaked at $101M in Q4 2021.
  • 272 funds tracked by Wall St. Rank held Omnicell as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.